Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: Report of 102 cases and review of literature

Kazuhiro Matsumoto, Nobuyuki Tanaka, Nozomi Hayakawa, Taisuke Ezaki, Kenjiro Suzuki, Takahiro Maeda, Akiharu Ninomiya, So Nakamura

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This retrospective chart review study was conducted to evaluate the efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in patients with castration-resistant prostate cancer (CRPC) and to determine who would benefit from EMP therapy. EMP was administered at a daily dose of 560 mg to 102 patients as a third-line therapy, who had already received combined androgen blockade (CAB) and subsequent alternative antiandrogen therapy. The responses to EMP after its induction and its toxicity were evaluated. We also analyzed the association between the clinicopathological factors of the patients and their responses to EMP therapy. A reduction in the serum prostate-specific antigen (PSA) 4 weeks after induction was observed in 70 patients (68.6 %), while 30 cases (29.4 %) achieved more than 50 % reduction of PSA. Long-term reduction of PSA from baseline for more than 6 months was observed in 31 patients (30.4 %). EMP treatment was discontinued in 11 patients (10.8 %) because of side effects (nausea in six patients, gynecomastia in three patients, eruption in one patient, and liver dysfunction in one patient). Multivariate analysis demonstrated that long duration of prior hormonal therapy was an independent favorable factor for reduced PSA levels, long responses, and overall survival. The data suggest that oral EMP administration as a third-line monotherapy is well tolerated and effective to some degree in patients with CRPC who have already received CAB and subsequent alternative antiandrogen therapy. Thus, EMP can be regarded as one treatment option, especially for patients whose prior duration of hormonal therapy was long.

Original languageEnglish
Article number717
JournalMedical Oncology
Volume30
Issue number4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Estramustine
Castration
Prostatic Neoplasms
Prostate-Specific Antigen
Androgen Antagonists
Complementary Therapies
Therapeutics
Androgens
Gynecomastia
Nausea
Oral Administration

Keywords

  • CRPC
  • EMP
  • Estramustine phosphate sodium hydrate
  • PSA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients : Report of 102 cases and review of literature. / Matsumoto, Kazuhiro; Tanaka, Nobuyuki; Hayakawa, Nozomi; Ezaki, Taisuke; Suzuki, Kenjiro; Maeda, Takahiro; Ninomiya, Akiharu; Nakamura, So.

In: Medical Oncology, Vol. 30, No. 4, 717, 2013.

Research output: Contribution to journalArticle

@article{bcc15254006d499f9363c5246679988e,
title = "Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: Report of 102 cases and review of literature",
abstract = "This retrospective chart review study was conducted to evaluate the efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in patients with castration-resistant prostate cancer (CRPC) and to determine who would benefit from EMP therapy. EMP was administered at a daily dose of 560 mg to 102 patients as a third-line therapy, who had already received combined androgen blockade (CAB) and subsequent alternative antiandrogen therapy. The responses to EMP after its induction and its toxicity were evaluated. We also analyzed the association between the clinicopathological factors of the patients and their responses to EMP therapy. A reduction in the serum prostate-specific antigen (PSA) 4 weeks after induction was observed in 70 patients (68.6 {\%}), while 30 cases (29.4 {\%}) achieved more than 50 {\%} reduction of PSA. Long-term reduction of PSA from baseline for more than 6 months was observed in 31 patients (30.4 {\%}). EMP treatment was discontinued in 11 patients (10.8 {\%}) because of side effects (nausea in six patients, gynecomastia in three patients, eruption in one patient, and liver dysfunction in one patient). Multivariate analysis demonstrated that long duration of prior hormonal therapy was an independent favorable factor for reduced PSA levels, long responses, and overall survival. The data suggest that oral EMP administration as a third-line monotherapy is well tolerated and effective to some degree in patients with CRPC who have already received CAB and subsequent alternative antiandrogen therapy. Thus, EMP can be regarded as one treatment option, especially for patients whose prior duration of hormonal therapy was long.",
keywords = "CRPC, EMP, Estramustine phosphate sodium hydrate, PSA",
author = "Kazuhiro Matsumoto and Nobuyuki Tanaka and Nozomi Hayakawa and Taisuke Ezaki and Kenjiro Suzuki and Takahiro Maeda and Akiharu Ninomiya and So Nakamura",
year = "2013",
doi = "10.1007/s12032-013-0717-2",
language = "English",
volume = "30",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients

T2 - Report of 102 cases and review of literature

AU - Matsumoto, Kazuhiro

AU - Tanaka, Nobuyuki

AU - Hayakawa, Nozomi

AU - Ezaki, Taisuke

AU - Suzuki, Kenjiro

AU - Maeda, Takahiro

AU - Ninomiya, Akiharu

AU - Nakamura, So

PY - 2013

Y1 - 2013

N2 - This retrospective chart review study was conducted to evaluate the efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in patients with castration-resistant prostate cancer (CRPC) and to determine who would benefit from EMP therapy. EMP was administered at a daily dose of 560 mg to 102 patients as a third-line therapy, who had already received combined androgen blockade (CAB) and subsequent alternative antiandrogen therapy. The responses to EMP after its induction and its toxicity were evaluated. We also analyzed the association between the clinicopathological factors of the patients and their responses to EMP therapy. A reduction in the serum prostate-specific antigen (PSA) 4 weeks after induction was observed in 70 patients (68.6 %), while 30 cases (29.4 %) achieved more than 50 % reduction of PSA. Long-term reduction of PSA from baseline for more than 6 months was observed in 31 patients (30.4 %). EMP treatment was discontinued in 11 patients (10.8 %) because of side effects (nausea in six patients, gynecomastia in three patients, eruption in one patient, and liver dysfunction in one patient). Multivariate analysis demonstrated that long duration of prior hormonal therapy was an independent favorable factor for reduced PSA levels, long responses, and overall survival. The data suggest that oral EMP administration as a third-line monotherapy is well tolerated and effective to some degree in patients with CRPC who have already received CAB and subsequent alternative antiandrogen therapy. Thus, EMP can be regarded as one treatment option, especially for patients whose prior duration of hormonal therapy was long.

AB - This retrospective chart review study was conducted to evaluate the efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in patients with castration-resistant prostate cancer (CRPC) and to determine who would benefit from EMP therapy. EMP was administered at a daily dose of 560 mg to 102 patients as a third-line therapy, who had already received combined androgen blockade (CAB) and subsequent alternative antiandrogen therapy. The responses to EMP after its induction and its toxicity were evaluated. We also analyzed the association between the clinicopathological factors of the patients and their responses to EMP therapy. A reduction in the serum prostate-specific antigen (PSA) 4 weeks after induction was observed in 70 patients (68.6 %), while 30 cases (29.4 %) achieved more than 50 % reduction of PSA. Long-term reduction of PSA from baseline for more than 6 months was observed in 31 patients (30.4 %). EMP treatment was discontinued in 11 patients (10.8 %) because of side effects (nausea in six patients, gynecomastia in three patients, eruption in one patient, and liver dysfunction in one patient). Multivariate analysis demonstrated that long duration of prior hormonal therapy was an independent favorable factor for reduced PSA levels, long responses, and overall survival. The data suggest that oral EMP administration as a third-line monotherapy is well tolerated and effective to some degree in patients with CRPC who have already received CAB and subsequent alternative antiandrogen therapy. Thus, EMP can be regarded as one treatment option, especially for patients whose prior duration of hormonal therapy was long.

KW - CRPC

KW - EMP

KW - Estramustine phosphate sodium hydrate

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=84891870018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891870018&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0717-2

DO - 10.1007/s12032-013-0717-2

M3 - Article

C2 - 24005812

AN - SCOPUS:84891870018

VL - 30

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

M1 - 717

ER -